Combivent Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 24 US drug patents filed from 2013 to 2015. Out of these, 5 drug patents are active and 19 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 16, 2030. Details of Combivent Respimat's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) | Active |
| US7837235 | Device for clamping a fluidic component |
Mar, 2028
(2 years from now) | Active |
| US9027967 | Device for clamping a fluidic component |
Mar, 2027
(1 year, 10 months from now) | Active |
| US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 4 months from now) | Active |
| US7896264 | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(14 days from now) | Active |
| US7284474 | Piston-pumping system having o-ring seal properties |
Aug, 2024
(8 months ago) |
Expired
|
| US7988001 | Container provided with a pressure equalization opening |
Aug, 2021
(3 years ago) |
Expired
|
| US6988496 | Cartridge for a liquid |
Feb, 2020
(5 years ago) |
Expired
|
| US7802568 | Cartridge for a liquid |
Feb, 2019
(6 years ago) |
Expired
|
| US6977042 | Microstructured filter |
Aug, 2018
(6 years ago) |
Expired
|
| US6846413 | Microstructured filter |
Aug, 2018
(6 years ago) |
Expired
|
| US6149054 | Mechanical counter for a metering apparatus |
Dec, 2016
(8 years ago) |
Expired
|
| US6453795 | Locking mechanism for a spring-actuated device |
Dec, 2016
(8 years ago) |
Expired
|
| US6726124 | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) |
Expired
|
| US5964416 | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) |
Expired
|
| US6176442 | Device for mounting a component exposed to a pressurized fluid |
Oct, 2016
(8 years ago) |
Expired
|
| US7104470 | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) |
Expired
|
| US7246615 | Atomising nozzle and filter and spray generating device |
May, 2016
(8 years ago) |
Expired
|
| US5662271 | Atomizing devices and methods |
Sep, 2014
(10 years ago) |
Expired
|
| US6007676 | Atomizing nozzle and filter and spray generating device |
Sep, 2013
(11 years ago) |
Expired
|
| US6503362 | Atomizing nozzle an filter and spray generating device |
Sep, 2013
(11 years ago) |
Expired
|
| US5911851 | Atomizing nozzle and filter and spray generating device |
Sep, 2013
(11 years ago) |
Expired
|
| US5472143 | Atomising nozzle and filter and spray generation device |
Sep, 2013
(11 years ago) |
Expired
|
| US5497944 | Atomising devices and methods |
Mar, 2013
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Combivent Respimat's patents.
Latest Legal Activities on Combivent Respimat's Patents
Given below is the list of recent legal activities going on the following patents of Combivent Respimat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 04 Sep, 2023 | US7988001 |
| Maintenance Fee Reminder Mailed Critical | 20 Mar, 2023 | US7988001 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2022 | US9027967 |
| Expire Patent Critical | 31 Oct, 2022 | US7802568 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 May, 2022 | US7837235 |
| Maintenance Fee Reminder Mailed Critical | 16 May, 2022 | US7802568 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Nov, 2021 | US8733341 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Dec, 2019 | US7396341 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Apr, 2019 | US7284474 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Jan, 2019 | US7988001 |
FDA has granted several exclusivities to Combivent Respimat. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Combivent Respimat, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Combivent Respimat.
Exclusivity Information
Combivent Respimat holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Combivent Respimat's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Several oppositions have been filed on Combivent Respimat's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Combivent Respimat's generic, the next section provides detailed information on ongoing and past EP oppositions related to Combivent Respimat patents.
Combivent Respimat's Oppositions Filed in EPO
Combivent Respimat has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 12, 2012, by Knorr-Bremse Systeme Für Nutzfahrzeuge Gmbh. This opposition was filed on patent number EP2004006768W. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP2004006768W | Apr, 2012 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Revoked |
US patents provide insights into the exclusivity only within the United States, but Combivent Respimat is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combivent Respimat's family patents as well as insights into ongoing legal events on those patents.
Combivent Respimat's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combivent Respimat's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 16, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combivent Respimat Generic API suppliers:
Albuterol Sulfate; Ipratropium Bromide is the generic name for the brand Combivent Respimat. 9 different companies have already filed for the generic of Combivent Respimat, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combivent Respimat's generic
How can I launch a generic of Combivent Respimat before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Combivent Respimat's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Combivent Respimat's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Combivent Respimat -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 100 mcg/20 mcg per actuation | 30 Mar, 2023 | 1 | 16 Oct, 2030 |
Alternative Brands for Combivent Respimat
There are several other brand drugs using the same active ingredient (Albuterol Sulfate; Ipratropium Bromide) as Combivent Respimat. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Albuterol Sulfate; Ipratropium Bromide, Combivent Respimat's active ingredient. Check the complete list of approved generic manufacturers for Combivent Respimat
About Combivent Respimat
Combivent Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. Combivent Respimat uses Albuterol Sulfate; Ipratropium Bromide as an active ingredient. Combivent Respimat was launched by Boehringer Ingelheim in 2011.
Approval Date:
Combivent Respimat was approved by FDA for market use on 07 October, 2011.
Active Ingredient:
Combivent Respimat uses Albuterol Sulfate; Ipratropium Bromide as the active ingredient. Check out other Drugs and Companies using Albuterol Sulfate; Ipratropium Bromide ingredient
Dosage:
Combivent Respimat is available in spray, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.1MG BASE/INH;0.02MG/INH | SPRAY, METERED | Prescription | INHALATION |